Company intelligence / Profile preview

RenalTech

Fountain Valley, California, United States

Ownership: Public · MARS
Development stage: Other

Overview

RenalTech is a veterinary health technology company that developed a predictive diagnostic tool for chronic kidney disease (CKD) in cats. The company's flagship AI-driven platform uses routine blood and urine test data to predict the onset of CKD up to two years before clinical signs appear. By leveraging a massive database of clinical records, RenalTech enables veterinarians to implement early interventions and personalized care plans. The company was acquired by Mars Petcare and its technology is now integrated into the diagnostic offerings of Antech Diagnostics and Royal Canin.

Therapeutic areas: Nephrology
Modalities: DiagnosticAlgorithmArtificial Intelligence
Industry: Veterinary

Partnerships

Antech DiagnosticsRoyal CaninVCA Animal Hospitals

Beyond the preview

Go deeper on RenalTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RenalTech.

Explore the full profile